20-F: Ascendis Pharma Reports Full Year 2024 Results, Highlights Progress in Endocrinology and Oncology

Ascendis Pharma's 20-F filing summarizes the company's financial performance, key developments, and future outlook, emphasizing its focus on endocrinology, rare diseases, and oncology.

Summary

• Ascendis Pharma reported a net loss of 378.1 million for the year ended December 31, 2024, and a net loss of 481.4 million for the year ended December 31, 2023.
• As of December 31, 2024, the company's total equity was negative by 105.7 million, compared to a negative balance of 145.7 million as of December 31, 2023.
• The company believes its existing cash and cash equivalents of 559.5 million will be sufficient to fund operations for at least the next twelve months.
• Key products include SKYTROFA for pediatric growth hormone deficiency and YORVIPATH for hypoparathyroidism in adults.
• The company is pursuing orphan drug designation for some of its product candidates.
• The company relies on third parties for manufacturing and clinical trials.
• The company faces intense competition in the biotechnology and pharmaceutical industries.
• The company is subject to ongoing regulatory obligations and review, which may result in significant additional expenses.
• The company is subject to healthcare laws, regulation and enforcement; failure to comply with these laws could harm results of operations and financial conditions.
• The company is subject to global anti-corruption laws, including but not limited to the U.S. Foreign Corrupt Practices Act, and non-compliance with such laws can subject the company to criminal or civil liability and harm the business, financial condition and results of operations.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as revenue growth and strategic collaborations, the significant net loss and negative equity raise concerns. The company's reliance on third parties and the competitive landscape also contribute to a neutral sentiment.

Positives

• The company believes its existing cash and cash equivalents of 559.5 million will be sufficient to fund operations for at least the next twelve months.
• The company has over 425 issued patents and over 525 patent applications as of December 31, 2024.
• The company has granted VISEN exclusive rights to develop and commercialize TransCon hGH, TransCon PTH and TransCon CNP in Greater China.
• In November 2023, the company entered into an exclusive license agreement with Teijin Limited to develop and commercialize TransCon hGH, TransCon PTH and TransCon CNP for certain endocrinology rare diseases in Japan.
• In January 2024, the company announced the formation of Eyconis, Inc. to develop, manufacture, and commercialize TransCon ophthalmology assets globally.

Negatives

• Ascendis Pharma reported a net loss of 378.1 million for the year ended December 31, 2024.
• As of December 31, 2024, the company's total equity was negative by 105.7 million.
• The company relies on third parties to manufacture and conduct clinical trials.
• The company faces intense competition in the biotechnology and pharmaceutical industries.
• The company is subject to ongoing regulatory obligations and review, which may result in significant additional expenses.
• The company is subject to healthcare laws, regulation and enforcement; failure to comply with these laws could harm results of operations and financial conditions.
• The company is subject to global anti-corruption laws, including but not limited to the U.S. Foreign Corrupt Practices Act, and non-compliance with such laws can subject the company to criminal or civil liability and harm the business, financial condition and results of operations.

Risks

• The company may seek additional financing to achieve its goals, and a failure to obtain this capital if needed on acceptable terms, or at all, could force the company to delay, limit, scale back or cease commercialization activities, product development or any other or all operations.
• The company is substantially dependent on the success of its products and product candidates, which may not be successful in nonclinical studies or clinical trials, receive regulatory approval or be successfully commercialized.
• Clinical drug development involves a lengthy and expensive process with uncertain outcomes, and the company may encounter substantial delays in its clinical studies.
• Competition in the biotechnology and pharmaceutical industries is intense and the company's competitors may discover, develop or commercialize products faster or more successfully than the company.
• The company relies on third-parties to manufacture preclinical, clinical and commercial supplies of its products, product candidates and their device components.
• The parent drug, drug product and other components of the company's products and product candidates are currently acquired from certain single-source suppliers.
• The loss of these suppliers, or their failure to supply could materially and adversely affect the company's business.
• The regulatory approval processes of the EMA, the FDA, and comparable authorities are lengthy, time consuming, and inherently unpredictable.
• Failure to obtain or maintain adequate coverage and reimbursement for the company's product candidates could limit the company's ability to market those products and decrease the company's ability to generate revenue.
• If the company is sued for allegedly infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in such litigation could harm the company's business.
• The potential effects of geopolitical conflicts, such as the military conflict between Russia and Ukraine and the conflict between Israel and Hamas could materially adversely impact the company's business, including the company's clinical trials, supply chain operation, regulatory timelines and commercial activities.
• Worldwide pandemics could materially adversely impact the company's business, including the company's clinical trials, supply chain operation, regulatory timelines and commercial activities.

Future Outlook

Based on the current operating plan, the company estimates that its existing cash and cash equivalents will be sufficient to fund its operations for at least the next twelve months from the date of this annual report.

Industry Context

The document highlights the competitive landscape in the biotechnology and pharmaceutical industries, noting the presence of established competitors and the potential for new entrants. It also mentions the increasing emphasis on cost-containment initiatives in healthcare, which may put pressure on pricing and usage of the company's products.

Comparison to Industry Standards

• The document mentions competitors such as Novo Nordisk, Pfizer, and BioMarin, who have already received regulatory approvals for products addressing similar therapeutic areas.
• Novo Nordisk has received regulatory approval of once-weekly somapacitan (brand name SOGROYA) for replacement of endogenous growth hormone in adult patients with GHD in the United States, Japan, Europe, Australia and Saudi Arabia and in pediatric patients with GHD in the United States, Japan, Europe, Canada, Brazil and Saudi Arabia.
• Pfizer (in collaboration with OPKO Health Inc.) has received regulatory approval of once-weekly somatrogon (brand name NGENLA) in more than 40 countries for pediatric GHD.
• BioMarin has received regulatory approval for vosoritide (brand name VOXZOGO) in more than 40 active markets for the treatment of achondroplasia.

Related Party Transactions

• The company has provided research and development services to VISEN Pharmaceuticals (VISEN) under its Rights Agreements which will be reimbursed by VISEN.
• Under the company's Rights Agreements, clinical supply agreements, purchase agreement and commercial supply agreement, the company has provided and agreed to provide product supply to VISEN for use in Greater China.
• The company has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company.
• In connection with the formation of Eyconis, the company has provided various administrative and support services under its Transitional Services Agreement.
• Under the company's Inventory Transfer Agreement and Material Transfer Agreement, the company has sold laboratory and office inventory, materials and assigned certain contract manufacturers contracts to Eyconis.
• Under the company's Sublease Agreement, the company has subleased R&D and laboratory facilities to Eyconis, initially until December 2025.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by changes in the company's strategic direction and resource allocation.
• Patients may benefit from the development and commercialization of new therapies.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company plans to submit a New Drug Application (NDA) for the treatment of children with achondroplasia during the first quarter of 2025.
• The company plans to submit a Marketing Authorisation Application (MAA) for the treatment of children with achondroplasia to the EMA during the third quarter of 2025.
• The company plans to submit an Investigational New Drug (IND) application or similar for a basket trial evaluating other indications (planned for small for gestational age without catch-up growth (SGA); idiopathic short stature (ISS); SHOX deficiency (including Turner syndrome)) during the third quarter of 2025.

Key Dates

Keywords

TransCon, SKYTROFA, YORVIPATH, clinical trials, regulatory approval, pharmaceutical, biotechnology, GHD, hypoparathyroidism, oncology